SGLT2 inhibitors modestly improve hemoglobin A1c (HbA1c) in patients with T2D but have additional benefits for weight loss and blood pressure reduction, due to calorie loss in the urine. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.